administered

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Source Node:
Time Stamp: December 29, 2023 3:07 AM - Modified On: December 29, 2023 - Published By:
Source Cluster:
Republished By Plato

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:16 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis in

Web23 and NexBLOC using Butterfly Protocol for Creating a Blockchain Naming System on the Cardano Blockchain Platform

Source Node:
Time Stamp: September 28, 2021 11:07 AM - Modified On: September 28, 2021 - Published By:
Source Cluster:
Republished By Plato

The Blockchain Domain Registry System will focus on enabling the Cardano community to maximize the use of blockchain domains British Virgin Islands Web23 Inc., a USA company, and NexBLOC, a British Virgin Islands company, are partnering to develop a blockchain-based naming system that runs natively on the Cardano blockchain platform. The initiative continues the move of the Butterfly Protocol onto numerous blockchains to ensure that those communities have the tools needed for full decentralized internet optimization. The Butterfly Protocol was originally created using the Ethereum blockchain and continues to provide